News Agencies Feed 

HEALTHCARE

ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations
December 7, 2016

Celgene Corporation (NASDAQ:CELG) today announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with advanced non-small cell lung cancer (NSCLC). Interim data being presented from the ABOUND trials during the IASLC 17th World Conference on Lung Cancer (WCLC) reinforces the benefit of ABRAXANE/carboplatin doublet therapy in first-line"...

Continue Reading >

Clinically meaningful data for oral nintedanib in mesothelioma presented at World Conference on Lung Cancer
December 7, 2016

  • Mesothelioma is a rare and difficult-to-treat cancer with no targeted treatment options currently approved
  • Oral triple angiokinase inhibitor nintedanib meets primary endpoint of progression-free survival (9.4 vs 5.7 months) and significantly reduced the risk of disease progression by 44% in Phase II study versus standard of care
  • Phase III extension trial (LUME-Meso [NCT01907100]) is currently"...

    Continue Reading >

Saudi officials announce 4 new MERS cases
December 5, 2016

Saudi Arabia's Ministry of Health (MOH) reported four new MERS-CoV cases in the past 3 days, including two from the holy city Medina, as the World Health Organization (WHO) today fleshed out more details about nine of the country's recently reported cases, four of which had a history of contact with camels or raw camel milk.

The new cases are part of a small but steady stream of cases from"...

Continue Reading >

Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-to-Treat Chronic Lymphocytic Leukaemia
December 5, 2016

AstraZeneca and its haematology Centre of Excellence, Acerta Pharma, today announced preliminary results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat forms of chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.1 The trial includes data from individuals with intolerance to ibrutinib and those with Richter transformation, when CLL transforms into"......

Continue Reading >

Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
December 4, 2016

– Data will be presented in an oral session at the annual American Society of Hematology (ASH) meeting on Saturday, December 3 at 2:15 p.m. PT –

– Trial achieved highly statistically significant improvements in rate of objective response lasting at least four months, median progression-free survival and overall response rate, and decrease in symptom burden in ADCETRIS arm;"...

Continue Reading >

New drug brings hope to 2 million asthma patients in Kingdom
December 3, 2016

The World Health Organization (WHO) has estimated that there are around 235 million people suffering from asthma globally and the Saudi Ministry of Health has announced recently that around 10 percent of adults as well as 20 percent of children in the Kingdom have asthma. This means there are 2 million asthma patients in Saudi Arabia, according to experts at a forum organized by the Saudi Thoracic Society at InterContinental Hotel in Jeddah on Friday.

During"...

Continue Reading >

Florida’s Parrish Medical Center is the First Hospital to Commit to All 12 Actionable Patient Safety Solutions (APSS)
December 2, 2016

The Patient Safety Movement Foundation (PSMF) is very proud to announce that Parrish Medical Center in Titusville, Florida, has become the first hospital to make formal commitments that align with all 12 Actionable"......

Continue Reading >

Cerevance Launched with New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases
December 2, 2016

Takeda Pharmaceutical Company Limited (TOKYO:4502):


- Takeda and Lightstone Ventures Participate in Series A Financing -


- Former Takeda Cambridge UK employees, CNS programs moved to create turn-key discovery capabilities -


Takeda"......

Continue Reading >

Fighting AIDS stigma ‘demands more awareness’ in Saudi Arabia
November 30, 2016

Social stigma over AIDS is still causing some patients to avoid treatment, a leading Saudi Arabia-based doctor said ahead of today’s global awareness campaign over the disease.
Knowledge about AIDS and HIV, the virus that can lead to it, is still poor even among some medical professionals, said Dr. Batool Ali, infectious diseases consultant at the Ministry of Health, based in Jeddah.
Despite global initiatives like today’s World AIDS Day, social stigma over the disease is still rife.
“Many people are still reluctant...

Continue Reading >

Visitors to Saudi Arabia 'granted 60 days' to submit health claims
November 30, 2016

Saudi Arabia has issued rules governing the forthcoming mandatory health insurance scheme for visitors.

The proposed scheme would require any visitor to the kingdom to opt into the scheme on arrival, with the exception of pilgrims, diplomats, international organisations and members of state – although local media reports ...

Continue Reading >